Introduction {#S0001}
============

Patients that are undergoing surgery or surgical procedures are at risk of acquiring infections at the site of incision. Surgical site infections (SSIs) are defined as infections occurring up to 30 days after surgery (or up to one year after surgery in patients receiving implants) and affecting either the incision or deep tissue at the operation site \[[@CIT0001]\]. Despite improvements in prevention, SSIs remain a significant clinical problem as they are associated with substantial mortality and morbidity and impose severe demands on healthcare resources \[[@CIT0002]\]. Microbiology studies on SSIs have shown that most of them are caused by skin-derived bacteria such as *Staphylococcus aureus* and coagulase-negative staphylococci \[[@CIT0002], [@CIT0003]\]. These bacteria, particularly methicillin resistant *Staphylococcus aureus* (MRSA) and methicillin resistant-coagulase negative staphylococci (MR-CNS) are known for they ability to develop resistance to multiple antibiotics \[[@CIT0004], [@CIT0005]\]. Studies on antimicrobial resistance of staphylococci and other bacteria isolated from hospitalized surgical patients were conducted in some African countries \[[@CIT0006]--[@CIT0009]\]. But in the Democratic Republic of Congo (DRC), the resistance pattern of *Staphylococcus*, especially MRSA and MR-CNS from SSIs to antibiotics remains unknown due to lack of antibiotic surveillance policies. The objective of the present study was to determine the prevalence and antibiotic susceptibility patterns of MRSA and MR-CNS isolated from SSIs in two major hospitals of Kinshasa.

Methods {#S0002}
=======

Origin of staphylococci strains and laboratory procedure {#S20003}
--------------------------------------------------------

This study was conducted between January to October 2013 in the Provincial General Reference Hospital of Kinshasa (HGPRK) and in Clinic of University of Kinshasa (CUK), a tertiary hospital structure. The clinical samples were collected for diagnostic purposes by the bacteriology laboratories of these hospitals and were from purulent lesions of infected sites of 130 hospitalized surgical patients. Infected sites were aseptically cleaned using normal saline and sterile gauzes. Then a wound swab from each patient was collected using sterile cotton swabs in Stuart transport media (Difco, BD Franklin Lakes, NJ, USA) and was processed in the microbiology laboratory of the Faculty of Pharmaceutical Sciences, University of Kinshasa.

Isolation and Identification of staphylococci {#S20004}
---------------------------------------------

Wound swabs were inoculated into mannitol-salt agar (Liofilchen, Roseto degli Abbruzzi, Italy) and incubated at 37°C for 24 hours. The genera *Staphylococcus* was confirmed using Gram staining and catalase reaction. The identification of *Staphylococcus aureus* strains was performed with latex agglutination test (Pastorex Staph-Plus, BioRad, Marnes-la-Coquette, France) and DNase test. All staphylococcal strains, negative for latex agglutination and DNase tests, were considered as coagulase negative staphylococci.

Antibiotic susceptibility tests {#S20005}
-------------------------------

Antibiograms of each isolated strains using the diffusion method on Mueller Hinton Agar were realized with the following antibiotic disks (Liofilchen, Roseto degli Abruzzi, Italy): amoxicillin-clavulanic acid (30 µg), ampicillin (10 µg), ciprofloxacin (5 µg), cefotaxime (30 µg), ceftazidime (30 µg), clindamycin (2 µg), erythromycin (15 µg), imipenem (10 µg), cotrimoxazole (25 µg), and vancomycin (30 µg). Test for methicillin resistance was performed with diffusion method using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl. Evaluation of the results was done according to the criteria of Clinical Laboratory Standards Institute (CLSI) \[[@CIT0010]\]. *S. aureus* ATCC 25923 and *Staphylococcus epidermidis* ATCC 12228 were used for quality control.

Results {#S0006}
=======

Eighty-nine staphylococci were isolated during the period of the study. Seventy-four strains were *S. aureus* and 15 strains were CNS. The *S. aureus* and CNS strains demonstrated good sensitivity patterns to imipenem, amoxicillin-clavulanic acid, and vancomycin. However, most *S. aureus* and CNS strains were resistant to ampicillin, cotrimoxazole, ciprofloxacin, erytromycin, clindamycin and ceftazidime ([Table 1](#T0001){ref-type="table"}, [Table 2](#T0002){ref-type="table"}). Out of the 74 *S. aureus* strains isolated, 47 (63.5%) were MRSA ([Table 3](#T0003){ref-type="table"}). All these strains were sensitive to imipenem, 39 strains (89%) to amoxicillin-clavulanic acid and 38 strains (81%) to vancomycin. Nine (60%) of 15 CNS strains were MR-CNS ([Table 4](#T0004){ref-type="table"}). All MR-CNS strains were fully sensitive to amoxicillin-clavulanic acid, imipenem, and vancomycin. The MRSA and MR-CNS strains demonstrated a high level of resistance to ampicillin, cotrimoxazole, erythromycin, clindamycin, ciprofloxacin, cefotaxime and ceftazidime. Multidrug resistance was observed in MRSA and MR-CNS strains ([Table 5](#T0005){ref-type="table"}).

###### 

Antibiotic susceptibility patterns of all *S. aureus* strains

                          *S. aureus* (n= 74)   
  ----------------------- --------------------- ------------
  Ampicillin              16 (21.6%)            58 (78.4%)
  Amoxicillin/Clav.acid   65 (88%)              9 (12%)
  Ceftazidime             37 (50%)              37 (50%)
  Cefotaxime              44 (59.5%)            30 (40.5%)
  Ciprofloxacin           24 (32.4%)            50 (67.6%)
  Clindamycin             22 (29.7%)            52 (70.3%)
  Cotrimoxazole           20 (27%)              54 (73%)
  Erythromycin            23 (31%)              51 (69%)
  Imipenem                74 (100%)             0 (0%)
  Vancomycin              63 (85%)              11 (15%)

###### 

Antibiotic susceptibility patterns of all CNS strains

                          CNS (n = 15)   
  ----------------------- -------------- ------------
  Ampicillin              6 (40%)        9 (60%)
  Amoxicillin/Clav.acid   14(93.3%)      1 (7.3%)
  Ceftazidime             7 (46.7%)      8 (53.3%)
  Cefotaxime              6 (40%)        9 (60%)
  Ciprofloxacin           1 (6.7%)       14(93.3%)
  Clindamycin             2 (13.3%)      13 (86.7%)
  Cotrimoxazole           5 (33.3%)      10 (66.7%)
  Erythromycin            4 (26.7%)      11 (73.3%)
  Imipenem                15 (100%)      0 (0%)
  Vancomycin              13 (86.7%)     2 (13.3%)

###### 

Antibiotic susceptibility patterns of MRSA strains

                          MRSA (n = 47)   
  ----------------------- --------------- ------------
  Ampicillin              5(10.6%)        42 (89.4%)
  Amoxicillin/Clav.acid   39 (89%)        8 (17%)
  Ceftazidime             22 (42%)        25 (53%)
  Cefotaxime              20 (42.6%)      27 (57.4%)
  Ciprofloxacin           20 (42.6%)      27 (57.4%)
  Clindamycin             15 (32%)        32 (68%)
  Cotrimoxazole           11 (23.4%)      36 (76.6%)
  Erythromycin            11 (23.4%)      36 (76.6%)
  Imipenem                47 (100%)       0 (0%)
  Vancomycin              38(81%)         9(19%)

###### 

Antibiotic susceptibility patterns of MR- CNS strains

                          (MR- CNS (n = 9)   
  ----------------------- ------------------ -----------
  Ampicillin              1(11.1%)           8 (88.9%)
  Amoxicillin/Clav.acid   9 (100%)           0 (0%)
  Ceftazidime             5 (55.6%)          4 (44.6%)
  Cefotaxime              3 (33.3%)          6 (66.7%)
  Ciprofloxacin           0 (0%)             9 (100%)
  Clindamycin             3 (33.3%)          6 (66.7%
  Cotrimoxazole           0 (0%)             9 (100%)
  Erythromycin            2 (22.2%)          7 (77.8%)
  Imipenem                9 (100%)           0 (0%)
  Vancomycin              9(100%)            0(0%)

###### 

Different resistance patterns of MRSA and MR-CNS strains

  Resistance pattern   MRSA (n= 47)   MR-CNS (n= 9)
  -------------------- -------------- ---------------
  1 AB                 0 (0%)         0 (0%)
  2 AB                 1 (2.1%)       0 (0%)
  3 AB                 5 (10.6%)      0 (0%)
  4 AB                 10 (21.2%)     3 (33.3%)
  5 AB                 10 (21.2%)     2 (22.2%)
  6 AB                 6 (12.7%)      1 (11.1%)
  7 AB                 7 (14.9%)      3(33.3%)
  8 AB                 4 (8.5%)       0 (0%)
  9 AB                 2 (4.2%)       0 (0%)

AB: antibiotic

Discussion {#S0007}
==========

The results obtained in the present study demonstrated high prevalence of MRSA (63.5%) and MR-CNS (60%). This prevalence is higher in comparison with other studies conducted in some African countries. Report from Uganda demonstrated that the proportion of MRSA among *S. aureus* strains isolated from SSIs was 37.5% \[[@CIT0006]\]. A survey conducted in Mulago National Referral Hospital (Uganda) on the surgical inpatients showed also an MRSA prevalence of 42% \[[@CIT0011]\]. However, our results are not consistent with those obtained in Bobo Dioulasso and Nairobi where very low MRSA prevalence was observed \[[@CIT0007], [@CIT0012]\]. Screening of MR-CNS isolates showed a high prevalence rate. Very few African studies have been focused on the prevalence of CNS SSIs \[[@CIT0013]\]. However, the current results are consistent with report from Switzerland in which the MR-CNS rate increased from 20% at the admission to 47% after surgery \[[@CIT0014]\]. The highest MRSA and MR-CNS prevalence observed in our study can be attributed to the high pressure use of broad spectrum antibiotics or to the long stay hospital \[[@CIT0015], [@CIT0016]\]. In general, MRSA is known to be transmitted mostly by health-care contacts \[[@CIT0017], [@CIT0018]\]. A Congolese study among nasal staphylococcal carriers reported an MRSA prevalence of 63.1%, 66.7% and 23.3% in hospitalized patients, hospital staff team and outpatients, respectively \[[@CIT0019]\]. Genomic characterization studies should be conducted in order to determine different genotypes of *Staphylococus aureus* strains circulating among SSIs patients and hospital staff. The MRSA and MR-CNS strains were generally multidrug resistant with an increasing resistance to ampicillin, cotrimoxazole, erythromycin, clindamycin, ciprofloxacin, ceftazidime and cefotaxime. This observation is in line with previous studies \[[@CIT0020], [@CIT0021]\]. The multidrug resistance observed is probably due to the ability of MRSA and MR-CNS strains to produce biofilms. Staphylococci are known as especially good biofilm formers, which is due primarily to the production of a series of surface molecules that promote extracellular matrix formation \[[@CIT0022]\]. Colonization of a biotic surface such as wound by *S. aureus* has been demonstrated *in vivo* in pigs and the biofilms formed were less susceptible to antimicrobials than the planktonic counterparts \[[@CIT0023]\].

A report from Italy also showed that *S. aureus* strains isolated from SSIs and producing a biofilm were highly resistant to antibiotic treatment \[[@CIT0024]\]. This observation suggests that bacteria within the wound or the surgical lesion are encased in an extracellular polymeric matrix, change their phenotype and become recalcitrant to antibiotics and to host defenses \[[@CIT0022]\]. None MR-CNS strain was resistant to amoxicillin-clavulanic acid, imipenem and vancomycine. We observed in the present study rates of Vancomycin Resistant *S. aureus* (VRSA) of 15% in all *S. aureus* strains and 19% in MRSA strains. Our findings were consistent with a previous report from Libya in which MRSA collected from different clinical specimens showed a VRSA prevalence of 17%, using disc-diffusion method \[[@CIT0025]\]. The increase of VRSA prevalence could be explained not only by the long use of vancomycin, but also by an infection or concurrent colonization with vancomycin resistant enterococci \[[@CIT0026]\].

Conclusion {#S0008}
==========

The results of the present study indicate that amoxicillin-clavulanic acid, imipenem and vancomycine should be recommended in the treatment of SSIs involving MRSA and MR-CNS. But, considering the emergence of multidrug resistant MRSA and MR-CNS strains, antibiotic susceptibility testing should be done prior to treatment in *S. aureus* and CNS surgical site infections.

We thank members of hospital staff teams of the General Reference Hospital of Kinshasa (HGPRK) and the Clinic of University of Kinshasa (CUK), Kinshasa, DRC for their precious help during the period of study.

Competing interests {#S0009}
===================

The authors declare no competing interest.

Authors' contributions {#S0010}
======================

Jean-Marie Liesse Iyamba contributed to the conception of the study, the analysis of the results and the preparation of the manuscript. Ntondo za Balega Takaisi-Kikuni contributed to the conception of the study and the preparation of manuscript. José Mulwahali Wambale contributed to the preparation of the manuscript. Cyprien Mbundu Lukukula contributed to the processing of samples. All the authors have read and approved the final version of the manuscript.
